Trenonacog alfa

Trenonacog alfa

Clinical data
Trade names	NovoEight
AHFS/Drugs.com	UK Drug Information
ATC code	B02BD02 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}

WikiDoc Resources for Trenonacog alfa
Articles
Most recent articles on Trenonacog alfa Most cited articles on Trenonacog alfa Review articles on Trenonacog alfa Articles on Trenonacog alfa in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Trenonacog alfa Images of Trenonacog alfa Photos of Trenonacog alfa Podcasts & MP3s on Trenonacog alfa Videos on Trenonacog alfa
Evidence Based Medicine
Cochrane Collaboration on Trenonacog alfa Bandolier on Trenonacog alfa TRIP on Trenonacog alfa
Clinical Trials
Ongoing Trials on Trenonacog alfa at Clinical Trials.gov Trial results on Trenonacog alfa Clinical Trials on Trenonacog alfa at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Trenonacog alfa NICE Guidance on Trenonacog alfa NHS PRODIGY Guidance FDA on Trenonacog alfa CDC on Trenonacog alfa
Books
Books on Trenonacog alfa
News
Trenonacog alfa in the news Be alerted to news on Trenonacog alfa News trends on Trenonacog alfa
Commentary
Blogs on Trenonacog alfa
Definitions
Definitions of Trenonacog alfa
Patient Resources / Community
Patient resources on Trenonacog alfa Discussion groups on Trenonacog alfa Patient Handouts on Trenonacog alfa Directions to Hospitals Treating Trenonacog alfa Risk calculators and risk factors for Trenonacog alfa
Healthcare Provider Resources
Symptoms of Trenonacog alfa Causes & Risk Factors for Trenonacog alfa Diagnostic studies for Trenonacog alfa Treatment of Trenonacog alfa
Continuing Medical Education (CME)
CME Programs on Trenonacog alfa
International
Trenonacog alfa en Espanol Trenonacog alfa en Francais
Business
Trenonacog alfa in the Marketplace Patents on Trenonacog alfa
Experimental / Informatics
List of terms related to Trenonacog alfa

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Turoctocog alfa (trade name NovoEight) is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A. It is marketed by Novo Nordisk. It was first launched in Germany in January 2014 and has been approved in the US, EU and Japan.

Medical uses

In the safety and efficacy trial for prevention and treatment of bleeds, in hemophilia patients the success rate for treatment of bleeds was 84.5% (excluding bleeds for which there was no outcome reported) and out of a total of nine surgeries in nine patients performed during the trial, haemostasis was successful in all the surgeries and no treatment failures were reported. It is also used for perioperative management and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. Turoctocog alfa is not indicated for the treatment of von Willebrand disease.

Benefits and risks

In a study conducted with 150 patients aged 12 and above, adolescents after using turoctocog alfa as a treatment, had an average of 5.55 bleedings per year while the adults had an average of 6.68 bleeding per year. According to data, turoctocog alfa was considered an 'excellent' treatment for 403 out of 499 bleeding episodes. In another study involving 63 patients aged less than 12 years, children had an average of 5.33 bleedings per year after using turoctocog alfa as hemophilia treatment. In this study too turoctocog alfa was considered as an 'excellent' treatment for 116 out of 126 bleeding episodes.

Alongside the benefits, a few of the common turoctocog alfa adverse effects would be injection site reaction, pyrexia and augmented liver enzyme levels. Rare cases of allergic reactions have been reported as well. There is a possibility of patients developing hypersensitivity to the drug since it contains traces of hamster proteins. Activity-neutralising antibodies (inhibitors) may be developed whereby expected plasma factor VIII activity levels may not be achieved and thus the bleeding would not be controlled as needed.

Preparation

As cell culture, Chinese hamster ovary cells (CHO) are used in order to acquire proper processing of factor VIII protein, that has demonstrated good efficacy in thrombin generation and clot formation in preclinical evaluations in murine (mouse) and canine (dog) models of hemophilia A and in patient-derived whole blood.

Difference between NovoSeven and NovoEight

Even though both treatments are plasma-derived and recombinant analogues of blood clotting factors, NovoSeven is developed as a congenital FVIIa analogue for hemophilia A and B patients while NovoEight (turoctocog alfa) is for congenital FVIII deficiency. NovoSeven is called a bypassing agent because it skips the need for factor VIII or IX in people with inhibitors and activates factor X directly.